Fas受体与冠状动脉支架内再狭窄研究进展  

Proceeding of Study Between Fas Receptor and Coronary Artery In-stent Restenosis

作　　者：朱玮玮[1] 郭成军[2] 赵林[2] 刘现亮[3] 

机构地区：[1]山东省滨州医学院附属医院心内科,山东滨州256603 [2]首都医科大学附属北京安贞医院心内6科,北京100029 [3]山东大学齐鲁医院,山东济南250012

出　　处：《心血管病学进展》2013年第6期735-737,共3页Advances in Cardiovascular Diseases

基　　金：首都医科大学基础与临床合作课题(13JL42)

摘　　要：经皮冠状动脉介入治疗是治疗冠状动脉粥样硬化性心脏病的主要手段。然而,目前最重要的问题是经皮冠状动脉介入治疗术后进一步形成支架内再狭窄。凋亡与支架内再狭窄相关。Fas及其配体FasL是启动凋亡的相关分子。现综述Fas及其配体FasL与冠状动脉支架内再狭窄的相关研究。Percutaneous coronary intervention has become one of the most important treatments for coronary artery disease . A major problem of coronary stenting is the development of in-stent restenosis. Apoptosis is thought to be associated with in-stent restenosis. Fas and Fas ligand（FasL） are molecules relevant to the initiation of apoptosis. This article reviews the current research progress of how Fas and FasL correlate with in-stent restenosis.

关 键 词：FASL FAS 支架内再狭窄 凋亡 冠状动脉粥样硬化性心脏病 

分 类 号：R541.4[医药卫生—心血管疾病]